Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

ECOG-ACRIN Cancer Research Group

Status: Completed

Conditions: Malignant Neoplasm; Primary Neoplasm; Recurrent Neoplasm; Smoking Cessation; Current Smoker; Carcinoma In Situ

Treatments: Other: Tobacco Cessation Counseling; Drug: Nicotine Replacement; Other: Survey Administration; Other: Behavioral, Psychological or Informational Intervention; Other: Quality-of-Life Assessment

Study type: Interventional

Funder types: NETWORK; NIH

Identifiers

NCT03808818

R01CA214427 (U.S. NIH Grant/Contract)

EAQ171CD (Other Identifier)

NCI-2018-02826 (Registry Identifier)

ECOG-ACRIN-EAQ171CD (Other Identifier)

Details and patient eligibility

About

This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part of their cancer care in community oncology practices. Virtual information and counseling sessions may help cancer patients quit smoking.

Full description

PRIMARY OBJECTIVE:

I. To compare the proportions of participants in the Enhanced Usual Care (EUC) and Virtual Tobacco Treatment (VIT) study arms with biochemically-verified 7-day point-prevalence abstinence from cigarettes at 6-months post enrollment.

SECONDARY OBJECTIVES:

I. Biochemically-verified 7-day point prevalence abstinence at 3-months follow-up.

II. Self-reported 7-day point prevalence cigarette abstinence at 3- and 6-months follow-up.

III. Significant reduction (> 50% reduction in reported number of cigarettes per day) in daily smoking from baseline to 3- and baseline to 6-months follow-up.

IV. Continuous (no self-reported smoking since last survey point) and sustained abstinence at 6 months (cotinine-verified at 3-months and 6-months).

EXPLORATORY OBJECTIVES:

I. To assess the potential effect of known and potential moderators on treatment effectiveness between the two arms.

II. To assess the processes of implementation and dissemination (acceptability, adoption, appropriateness, treatment fidelity, cost effectiveness, penetration/reach, and sustainability) of the investigator's intervention at community oncology sites.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A (Enhanced Usual Care [EUC]): Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the National Cancer Institute (NCI) Smoking Quitline.

ARM B (Virtual Intervention Treatment [VIT]): Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of nicotine replacement (NRT) (patch and lozenge combined or alone).

After completion of study, patients may be followed up for 1 year.

Enrollment: 306 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• STAFF ELIGIBILITY CRITERIA:

• Must be English speaking.

• Must be employed at NCI Community Oncology Research Program (NCORP) site for at least three months.

• PATIENT ELIGIBILITY CRITERIA STEP 0:

• Patient presenting with any type of cancer with a date of diagnosis within the past 4 months. Recurrence, diagnosed within the last 4 months, of tumors in patients with past cancer diagnoses will be considered eligible. Patients with a new primary cancer, diagnosed within the last 4 months, who have been treated previously for other types of cancer will also be considered eligible. ?In situ? cancers, diagnosed within the past 4 months, will also be considered eligible.

• Patient must be a current smoker. Current smoker is defined as any cigarette smoking (even a puff) in the past 30 days.

• Patient must be fluent in both, written and spoken, English or both, written and spoken, Spanish.

• Patient must have telephone, e-mail access, and have access to the internet with a camera-enabled device (e.g., smartphone, tablet, computer, laptop with a webcam/camera)

  • NOTE: The restriction to those with web and e-mail access is based on the primary intention of the study; to assess the implementation of the virtual intervention in the NCORP network.

• ELIGIBILITY CRITERIA STEP 1: Patient must still meet all criteria outlined in step 0.

• ELIGIBILITY STEP 2 (RANDOMIZATION): Patient must have completed baseline survey in Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group Systems for Easy Entry of Patient Reported Outcomes (EASEEPRO) within 1 month (30 days) of the date of informed consent (Step 1).

Exclusion criteria

• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or above, or is deemed medically unable to participate by study investigators or oncology clinician (i.e., referral to hospice).
• Patient has no intention to receive their cancer care or monitoring at an NCORP community cancer site.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

306 participants in 2 patient groups

Arm A (smoking assessment, quitting advice, Quitline referral)

Active Comparator group

Description:

Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.

Treatment:

Other: Quality-of-Life Assessment

Other: Behavioral, Psychological or Informational Intervention

Arm B (virtual counseling sessions, NRT)

Experimental group

Description:

Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).

Treatment:

Other: Quality-of-Life Assessment

Other: Survey Administration

Other: Tobacco Cessation Counseling

Drug: Nicotine Replacement